Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis. Calleja JL, et al. Among authors: arenas ji. Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15. Liver Int. 2015. PMID: 25113158 Clinical Trial.
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.
Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, Diago M, Bonet L, Gallego A, García-Samaniego J, Testillano M, Rodríguez M, Castellano G, Gutiérrez ML, Delgado M, Mas A, Romero-Gómez M, Calleja JL, González-Guirado A, Arenas JI, García-Buey L, Andrade R, Gila A; ORIENTE-2 study group. Buti M, et al. Among authors: arenas ji. Eur J Gastroenterol Hepatol. 2015 Jan;27(1):46-54. doi: 10.1097/MEG.0000000000000195. Eur J Gastroenterol Hepatol. 2015. PMID: 25341057
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J, Díaz R, Hernandez-Guerra M, Gómez M, Castells L, Bustamante J, Espinosa MD, Fernández-Castroagudín J, Serrano T, Rendón P, Andrade R, Salgado M, Arenas J, Vergara M, Sala M, Polo BA, Granizo IM, Gonzálvez ML, Viudez A. Turnes J, et al. Gastroenterol Hepatol. 2015 Apr;38(4):263-73. doi: 10.1016/j.gastrohep.2014.11.001. Epub 2015 Jan 9. Gastroenterol Hepatol. 2015. PMID: 25583146 Clinical Trial. Spanish.
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers.
Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Rodríguez de Lope C, et al. Among authors: arenas ji. Med Clin (Barc). 2017 Jul 21;149(2):61-71. doi: 10.1016/j.medcli.2016.12.048. Epub 2017 Mar 7. Med Clin (Barc). 2017. PMID: 28279536 Clinical Trial. English, Spanish.
The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M, Castells L, Pascual S, Fernández-Castroagudín J, Díez-Miranda I, Irurzun J, Díaz-Beveridge R, Senosiaín M, Arenas J, de la Mata M, Turnes J, Monge-Romero MI, Pérez-Enguix D, Bustamante-Schneider J, Otegui N, Molina-Pérez E, Rodríguez-Menéndez JE, Varela M. Pipa-Muñiz M, et al. Gastroenterol Hepatol. 2017 Oct;40(8):515-524. doi: 10.1016/j.gastrohep.2017.05.009. Epub 2017 Jul 1. Gastroenterol Hepatol. 2017. PMID: 28676199 English, Spanish.
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Llaneras J, et al. J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14. J Hepatol. 2019. PMID: 31203153 Free article. Clinical Trial.
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
Díaz-González Á, Sanduzzi-Zamparelli M, da Fonseca LG, Di Costanzo GG, Alves R, Iavarone M, Leal C, Sacco R, Matilla AM, Hernández-Guerra M, Aballay Soteras G, Wörns MA, Pinter M, Varela M, Ladekarl M, Chagas AL, Mínguez B, Arenas JI, Granito A, Sánchez-Torrijos Y, Rojas Á, Rodríguez de Lope C, Alvares-da-Silva MR, Pascual S, Rimassa L, Lledó JL, Huertas C, Sangro B, Giannini EG, Delgado M, Vergara M, Perelló C, Lue A, Sala M, Gallego A, Coll S, Hernáez T, Piñero F, Pereira G, França A, Marín J, Anders M, Mello V, Lozano M, Nault JC, Menéndez J, García Juárez I, Bruix J, Reig M. Díaz-González Á, et al. Among authors: arenas ji. Liver Int. 2020 Jun;40(6):1467-1476. doi: 10.1111/liv.14436. Epub 2020 Apr 15. Liver Int. 2020. PMID: 32170821
168 results